Eledon pharmaceuticals announces use of tegoprubart in first-ever transplant of genetically modified kidney from a pig to a human

Historic kidney xenotransplantation procedure conducted at massachusetts general hospital tegoprubart administration has now been used investigationally to prevent rejection in both kidney and heart pig-to-human xenotransplantations, as well as in human-to-human kidney transplantation eledon recently presented results from its ongoing phase 1b kidney transplantation study which demonstrated that tegoprubart was generally safe and well tolerated and successfully prevented rejection with post-transplant kidney function above historical averages irvine, calif., march 21, 2024 (globe newswire) -- eledon pharmaceuticals, inc. (“eledon”) (nasdaq: eldn) today announced that tegoprubart, the company's investigational anti-cd40l antibody, was used as a component of the immunosuppressive treatment regimen following the first-ever transplant of a kidney from a genetically modified pig to a human.
ELDN Ratings Summary
ELDN Quant Ranking